Singapore markets close in 5 hours 47 minutes
Straits Times Index
3,353.95 +15.38 (+0.46%) Nikkei
39,780.58 +149.52 (+0.38%) Hang Seng
17,828.57 +109.96 (+0.62%) FTSE 100
8,166.76 +2.64 (+0.03%) Bitcoin USD
62,963.38 -445.82 (-0.70%) CMC Crypto 200
1,344.19 +42.12 (+3.23%)
PCVX Sep 2024 50.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:07PM EDT. Market open.
| Previous close | 3.0500 |
| Open | 2.9000 |
| Bid | 0.6000 |
| Ask | 5.0000 |
| Strike | 50.00 |
| Expiry date | 2024-09-20 |
| Day's range | 2.9000 - 2.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 7 |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.